New LaunchJun 25, 2026, 09:07 AM
Dare Bioscience to Launch Flora Sync LF5™ Vaginal Probiotic in June 2026
AI Summary
Dare Bioscience announced its participation in a Virtual Investor segment highlighting the upcoming June 2026 commercial launch of Flora Sync LF5™. This vaginal probiotic capsule is the company's first consumer health product, positioning Dare for direct revenue generation. The launch is a significant step in expanding its women's health leadership platform and diversifying its portfolio while advancing clinical-stage programs.
Key Highlights
- Dare Bioscience announced the upcoming June 2026 commercial launch of Flora Sync LF5™.
- Flora Sync LF5™ is a vaginal probiotic capsule designed to restore microbiome balance.
- This product marks the company's first consumer health product.
- The launch is expected to generate direct product revenue for Dare Bioscience.
- Flora Sync LF5™ aligns with Dare's strategy to build a diversified women's health company.
Price Impact
More from DARE